Clinical Trial

Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC

Name: Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC — clinical trial record (NCT07136285)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

Oncolytic virus product named Olvi-Vec combined with Platinum plus Etoposide in patients with late phase SCLC

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2025-08-14; most recent amendment 2025-11-25.

Trial Details

NCT Number	NCT07136285
Lead Sponsor	Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. Collaborators: Genelux Corporation
Conditions	SCLC, Extensive Stage
Enrollment	27 participants
Start Date	2023-07-24
Primary Completion	2026-12 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2025-12-03